Why is the CSL share price sliding lower on Monday?

Investors should be stoked with CSL's share price drop today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a rough start to the week for the S&P/ASX 200 Index (ASX: XJO) and ASX shares. At the time of writing, the ASX 200 has opened 0.14% lower so far this Monday. But let's talk about the CSL Limited (ASX: CSL) share price. 

If you thought the ASX 200's start to the week was disappointing, wait until you see what's going on with CSL shares. The ASX 200 healthcare stock closed last week at a share price of $270.85. But this morning, CSL opened at $269 a share and is currently going for just $266.65 at the time of writing, down a nasty 1.55% for the day so far.

Before any CSL investors get carried away with wondering what's going wrong with their investment today, it's worth pointing out that there's a good reason for CSL's rather steep drop this Monday. This healthcare share has just traded ex-dividend for its upcoming shareholder payment.

woman testing substance in laboratory dish, csl share price

Image source: Getty Images

CSL share price stutters as company trades ex-dividend

Last month, we analysed CSL's latest earnings report, covering the full 2023 financial year. It was a well-received earnings report at the time, with the healthcare giant revealing that it had managed to grow revenues by a healthy 31% in constant currency terms to US$13.31 billion.

Net profits after tax before amortisation rose by 20% in constant currency to US$2.86 billion, while reported net profits lifted by 10% to US$2.61 billion.

That enabled CSL to boost its final dividend for 2023 by 9.3% to US$1.29 per share, partially franked at 10%. That's the largest dividend CSL has ever paid out. This payment takes the company's full-year dividends to US$2.36 per share, up 6% from last year.

However, as we warned last week, CSL's ex-dividend date for this supersized shareholder payment is today. This means that anyone buying CSL shares from today onwards is not eligible to receive this latest dividend.

That's why we are seeing such a dramatic fall in the CSL share price this Monday relative to the ASX 200. It usually happens when an ASX share trades ex-dividend, and reflects this inherent loss of value for new investors going forward.

So existing CSL investors have nothing to complain about with their company seeing a share price drop today. It's the best reason to see a company have a red day on the markets.

CSL shareholders can now look forward to receiving their latest dividend next month on 4 October.

Right now, CSL shares have a dividend yield of 1.15%. The CSL share price remains down by 5.5% in 2023 to date, as well as by 10.1% over the past 12 months, as you can see below:

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Broker Notes

3 reasons to buy Pro Medicus shares today

Two leading investment analysts believe Pro Medicus shares are primed for a rebound.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Healthcare Shares

Should I invest $10,000 into CSL shares? Yes or no

Is it time to pick up this fallen giant? Let's dig deeper into things.

Read more »

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »